Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Firefly discovers novel electrophysiological biomarker for PTSD

Firefly Neuroscience (NASDAQ: AIFF) has announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using brain scans collected on its FDA-510(k)-cleared Evoke System...

June 2, 2026

Developments

Senzime launches new EMG sensor for anesthesia monitoring

Senzime (STO: SEZI; OTCQX: SNZZF) has announced the launch of its TetraSens electromyography (EMG) sensor for use with the TetraGraph Train-of-Four monitoring system for anesthesia monitoring. According to Senzime, the...

June 1, 2026

Developments

Sunshine announces Canadian approval of generic Rivaroxaban

Sunshine Biopharma (NASDAQ: SBFM) has announced the Canadian approval of Rivaroxaban—its generic equivalent of the brand Xarelto—in tablets of 2.5 mg, 10 mg, 15 mg, and 20 mg for the treatment and prevention of deep...

June 1, 2026

Developments

Cercare and Siemens announce global collaboration on CBCT-P guided stroke treatment

Closely held Cercare Medical and Siemens Healthineers (FSE: SHL) have announced a global collaboration to accelerate the adoption of Cone-Beam CT Perfusion (CBCT-P) in acute stroke care, leveraging its capability to...

May 28, 2026

Developments

BioXcel presents positive data for BXCL501 in bipolar or schizophrenia at ASCP

BioXcel Therapeutics (NASDAQ: BTAI) has announced new positive Phase 3 SERENITY At-Home data for BXCL501 in agitation associated with bipolar disorders or schizophrenia, to be presented this week at the 2026 American...

May 28, 2026

Developments

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Conexeu Sciences (NASDAQ: CNXU) has initiated a preclinical development program for B.R.E.A.S.T. (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE), its recently unveiled 3D-printed bioregenerative breast matrix...

May 28, 2026

Developments

The iMRI revolution gets another boost from AiM’s collaboration with Siemens to advance robotic neurosurgery

Closely held AiM Medical Robotics has announced a collaboration agreement with Siemens Healthineers (FSE: SHL) for the implementation of an interface enabling AiM’s robotic platform to operate with MRI systems...

May 27, 2026

Developments

Kura reports compelling data from trial of FTI in solid tumors

Kura Oncology (NASDAQ: KURA) has reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily...

May 26, 2026

Developments

Percheron secures pINN from WHO for investigational cancer therapy

Percheron Therapeutics (ASX: PER; OTC: PERCF) has secured a potential international nonproprietary name (pINN) from the World Health Organization (WHO) for its investigational cancer therapy HMBD-002. According to...

May 26, 2026

Developments

Assembly broadens program into cholestatic liver diseases

Assembly Biosciences (NASDAQ: ASMB) has announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary...

May 22, 2026

Developments

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced that Royal Columbian Hospital (RCH) has dosed its first patient in the ongoing Phase 2 trial evaluating LSALT peptide as a new drug to prevent acute kidney...

May 22, 2026

Developments

Adagio submits PMA for vCLAS Ventricular Ablation System for VT

Adagio Medical Holdings (NASDAQ: ADGM) has announced the submission of its Premarket Approval (PMA) application to the FDA for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent...

May 21, 2026

Developments

Medtronic to buy SPR Therapeutics for ~$650 million

Medtronic (NYSE: MDT) announced its intent to acquire SPR Therapeutics, a closely held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for...

May 20, 2026

Developments

Envoy expands IP portfolio with new patents in fully implanted hearing technology

Envoy Medical (NASDAQ: COCH) has announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the company’s intellectual...

May 20, 2026

Developments

CRC approves Cohort 2 opening of nimacimab expansion study

Skye Biosciences (NASDAQ: SKYE) has announced that the Cohort Review Committee (CRC) has approved opening the second cohort of the CBeyond Part C Expansion study of nimacimab in obesity, based on favorable safety data...

May 20, 2026

Developments

PharmaJet spotlights review in Qeios listing advantages of needle-free ID delivery v. traditional needle and syringe

Closely held PharmaJet has highlighted a peer-reviewed publication in the AI-powered open science publishing platform Qeios, which evaluated the evidence on implementation of novel technologies for intradermal (ID)...

May 19, 2026

Developments

Defence expands ADC platform with analytical and cellular testing

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has announced the expansion of internal capabilities to execute critical stages of its ACCUM-enabled antibody drug conjugates (ADC) development pipeline. According...

May 19, 2026

Developments

Telix in PSMA collaboration with Profound Medical and other prostate cancer therapy players

Telix Pharmaceuticals (ASX:TLX, NASDAQ:TLX) announced that it has entered into letters of intent to pursue collaborations to explore the investigational use of its PSMA-PET imaging agents Gozellix (kit for the...

May 15, 2026

Developments

BriaCell expands pipeline to ovarian cancer candidate

BriaCell Therapeutics (NASDAQ: BCTX, BCTXL; TSX: BCT) has announced progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. According to the...

May 15, 2026

Developments

Rigel enters into licensing agreement with Arvinas and Pfizer

Rigel Pharmaceuticals (NASDAQ: RIGL) has announced that it has entered into an exclusive, global license agreement with Arvinas (NASDAQ: ARVN) and Pfizer (NYSE: PFE), subject to regulatory clearance, to develop...

May 12, 2026

Developments

MindMaze and Vibra ink partnership to scale neurotherapeutics across U.S.

MindMaze Therapeutics (SIX: MMTX) has announced the signing of a definitive channel partnership agreement with closely held Vibra Healthcare to introduce MindMaze’s FDA-cleared digital neurotherapeutics platform to U.S...

May 12, 2026

Developments

4basebio launches enzymatic ssDNA platform

4basebio (AIM: 4BB) has announced the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene...

May 11, 2026

Subscribe